Koskenvuo 2019.

Study characteristics
Methods	Study design: Parallel‐group randomised trials Duration of trial: March 2016 to August 2018 Duration of follow‐up: Quote: ""During the hospital stay and at 1‐month clinical follow‐up visit at the outpatient clinic" Country of origin: Finland
Participants	Baseline characteristics Number randomised: 417 participants Number analysed: 396 participants Intervention: MBP+oAB Number of participants [n]: 196 Age [years; mean (range)]: 69.9 (61.1‐75.2) Gender [male/female; n]: 105/91 Control: nBP Number of participants [n]: 200 Age [years, mean (range)]: 70.3 (61‐76) Gender [male/female; n]: 96/104 Inclusion criteria  Quote: ""Patients scheduled for colon resection in participating centres. Both benign and malignant indications were eligible, as were both laparoscopic and open procedures." Exclusion criteria Quote: ""Need for emergency surgery; bowel obstruction; colonoscopy planned to be undertaken during surgery; other indications for mechanical preparation or contraindications; allergy to drugs used in the trial (polyethylene glycol, neomycin, metronidazole); and age younger than 18 years or older than 95 years." Baseline imbalances Quote: ""Patient baseline characteristics were similar between the two groups"
Interventions	Comparison Intervention: MBP+oAB Control: nBP MBP Agent(s): polyethylene glycol Dose per administration: 2000 mL Time(s) of intake: before 6 PM on day before surgery Route: oral Concomitant medications: ‐ oAB Agent(s): neomycin and metronidazole Dose per administration: 2 g each Time(s) of intake: Neomycin at 7 PM and metronidazole at 11 PM Route:oral Concomitant medications: ‐ Perioperative intravenous antibiotic prophylaxis Agent(s): cefuroxime and metronidazole Dose per administration: 1500 mg and 500 mg Time(s) of intake:Quote: ""At the start of anaesthesia before skin incision. The prophylactic intravenous antibiotics were re‐administered if the surgery lasted longer than 3 h from the first antibiotic dose, or if blood loss exceeded 1,5 L" Adherence to regimen: ‐
Outcomes	Outcomes sought in review and reported in trial SSI Anastomotic leakage Mortality Length of hospital stay Side effects of oAB Outcomes sought but not reported in trial Postoperative complications (mild D/C I + II or severe D/C III+IV) Incidence of postoperative ileus Side effects of MBP Outcomes reported in trial but not used in review Comprehensive Complication Index Prevalence of adjuvant therapy 5‐year overall survival
Notes	Source of funding: Quote: " "Vatsatautien Tutkimussäätiö Foundation, Mary and Georg Ehrnrooth’s Foundation, and Helsinki University Hospital research funds" Conflicts of interest: "VS reports grants from Vatsatautien Tutkimussäätiö Foundation, Mary and Georg Ehrnrooth’s Foundation, and Helsinki University Hospital research funds, during the conduct of the study; grants from Finnish Surgical Society, Finska Läkaresällskapet, and Finnish Gastroenterological Society; personal fees from City of Vantaa, Finnish Gastroenterological Society, Novartis, and University of Helsinki; and non‐financial support from Astellas, outside of the submitted work. TS reports personal fees from Johnson & Johnson’s laparoscopic colorectal surgery advisory board, outside of the submitted work. All other authors declare no competing interests" Ethics approval: Quote: ""The research plan was approved by the Finnish National Committee on Medical Research Ethics and Finnish Medicines Agency. The research plan was further approved by the local ethics committee of Helsinki University Hospital and by each participating centre’s institutional review board (Helsinki University Hospital, Oulu University Hospital, Central Finland Central Hospital, and Seinäjoki Central Hospital)" Informed consent: Patients provided written informed consent Clinical trials registration: ClinicalTrials.gov (NCT02652637) and EudraCT (2015–004559–38) Sample size calculation: Quote: " "With a power of 80% and significance at 5%, 396 patients would be needed to show this difference. The sample size was adjusted for a possible 5% loss, yielding a final sample size of 415 patients"